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New guidelines to evaluate the response to treatment in solid tumors using imaging techniques have major limitations and important
implications for radiological workload. This consensus statement from the International Cancer Imaging Society (ICIS) reviews the
RECIST criteria and addresses several challenges regarding tumour measurement. Recommendations are made regarding tumour
measurement and other issues are raised. The growing need to introduce a multimodality approach to monitoring response is
recognized. ICIS welcomes a dialogue with the authors of RECIST to address issues raised in this review.
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New guidelines to evaluate the response to treatment in solid
tumours were published in the Journal of the National Cancer
Institute in February 2000 (Therasse et al, 2000). These new
criteria were developed by a task force set up by the European
Organisation for Research and Treatment of Cancer (EORTC), the
National Cancer Institute (NCI) of the United States and the
National Cancer Institute of Canada Clinical Trials Group in an
attempt to address areas of conflict and inconsistency between
different methods of assessing response used in clinical research
throughout the world. It was hoped that these new criteria and
guidelines for their use would provide a standardised practical
approach, which could be adopted uniformly on a wide scale. In
defining the new Response Criteria In Solid Tumours (RECIST),
the group have recognised the pivotal role of imaging in response
assessment. They have acknowledged the need for continuous
appraisal of rapidly advancing imaging technology and are aware
of the need to develop functional imaging to provide surrogate end
points for ‘novel’ therapies. We applaud the reappraisal of
guidelines for therapy response assessment, especially in the light
of the rapid advances in medical imaging technology and
oncologic therapies. We are also grateful for the attempt to
standardise techniques in imaging included in RECIST; however,
these new criteria and guidelines have major limitations as well as
important implications for diagnostic radiological workload. In
this communication, we address our concerns regarding the use of
the RECIST criteria.
The International Cancer Imaging Society (ICIS) was founded in
1999 in order to promote education in cancer imaging and its role
in the multidisciplinary management of malignant disease. This
rapidly growing society currently has over 200 members worldwide
and holds an annual scientific meeting and postgraduate teaching
course. The vast majority of the associate members are radiologists
who have an interest in cancer radiology and the 38 full members
are all specialist oncological radiologists who are international
leaders in the field.
At the second annual course of ICIS, which was held in London
in October 2001, a symposium entitled ‘Monitoring Response to
Treatment’ provided the forum for a discussion of the difficulties
encountered in monitoring tumour response with imaging and, in
particular, the practical challenges of adopting the new RECIST
criteria. The discussion stimulated this review. We applaud the
standardisation of response assessment criteria and in particular
numerous features of RECIST, which address specific imaging
guidelines in clinical trials and considerations of other modalities
and techniques for response assessment. Many of the general
problems of monitoring tumour response with imaging have been
addressed in the literature previously (Thiesse et al, 1997).
However, we would like to share our views regarding the strengths
and weaknesses of using the RECIST criteria, and what other issues
should potentially be added to a response criterion with a wider
audience in the hope that we may be able to open discussion
between ICIS and the Task Force of the EORTC, the NCI and the
NCI (Canada). Our ultimate objective is to offer constructive
suggestions on the guidance for implementation of the RECIST
criteria.
 We recognise three important purposes for evaluation of
treatment response for reporting the outcome of clinical trials,
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lthat is, tumour response as a prospective end point in early
clinical trials, tumour response as a prospective end point in
more definitive clinical trials designed to provide an estimate of
benefit for a specific cohort of patients and tumour response as
a guide for the clinician and patient or study subject in
decisions about continuation of current therapy. We also
acknowledge the need to assess tumour response in daily
clinical practice. Although the protocols for imaging to assess
response for clinical trials are likely to differ considerably from
those required to assess individual clinical response in routine
practice, the key to accurate, reproducible assessment, for both
types of practice, is the involvement of a radiologist experienced
in oncological imaging. The assessment of response not only
requires an approximate estimate of tumour size, or more
precise measurement, but also requires an in-depth under-
standing of the complications of cancer therapies and a detailed
knowledge of the disease-specific patterns of tumour recur-
rence. The difference between imaging in clinical care and
imaging for clinical trials is subtle, especially for the non-
radiologist, but of paramount importance to obtain results that
are reproducible and consistent across centres. In some manner,
the difference in radiologic assessment is similar to differences
in practice for the chemotherapist practising in clinical care
versus enrolling and caring for a patient on a clinical trial.
 The new RECIST criteria do not allow for the comparison of
historical trials using WHO and current trials using RECIST.
The data from the eight clinical trials used in the RECIST
documentation were not referenced in the published criteria
and guidelines (Therasse et al, 2000). It is uncertain what
modality was used in these trials, what methodology was used to
calculate the measurements and how many tumours or
metastases were actually measured. Subsequent data have
demonstrated some concordance between RECIST and WHO
for best overall response but limited or no concordance between
RECIST and WHO for time to progression (Schwartz et al, 2001;
Warren et al, 2001; Prasad et al, 2002; Wang et al, 2003). This
criterion is increasingly being used as a surrogate end point and
the lack of correlation between RECIST and WHO is of concern.
Thus there is potential for inappropriate application of
noncomparable standards, which could potentially result in
imaging being viewed as a poor method for quantitatively
judging response. Furthermore, new drugs and therapies may
not be approved for clinical use or may not reach the stage of
full evaluation because of the application of differing standards
and the comparison to historical controls and clinical trials.
However, when appropriately applied, imaging represents one
of the best methods available for objective and quantifiable
response assessment.
The RECIST criteria aim to replace bidimensional assessment of
one or more target lesions with summation of unidimensional
assessments of many lesions: up to five in a single organ; up to 10
in total. These measurements aim simply to reflect categories of
treatment response as defined in the WHO criteria (Miller et al,
1981). The application of serial arithmetic assessment of the
RECIST criteria corresponds well with those of WHO within
the category of partial response. However, comparison of the
unidimensional method (RECIST) and the bidimensional method
(WHO) is discrepant for progressive disease. The RECIST criterion
of 20% increase in length to indicate progressive disease (PD) does
not equate to the 25% increase as judged by the WHO criteria.
Indeed a 20% increase in a unidimensional measurement using the
RECIST criterion equates to a 44% increase in bidimensional
measurement (Sohaib et al, 2000). This discrepancy is partially
discussed within the new guidelines, as a concern related to the
difficulty of measuring lesions that increase by 12% unidimen-
sionally (mathematically corresponding to the original bidimen-
sional WHO 25%). However, the difficulty or impact of the change
in response assessment for disease progression was not proven or
justified in the guidelines. Clearly, such a discrepancy will arguably
result in longer periods of progression-free disease and specifically
in changes in time to progression between new trials using the
RECIST criteria and those using WHO criteria (Warren et al, 2001;
Schwartz et al, 2003a).
 There are several challenges regarding tumour measurements.
* The RECIST criteria of adoption of a single measurement
(long axis) state that measurement is to be made only in the
axial plane for CT. With MR and multislice CT, longitudinal
or oblique measurements as well as axial measurements can
now be made readily. Three-dimensional (3D) assessment
and measurement of solid tumours is now available in many
institutions. Its widespread use will clearly depend upon
penetration of the acquisition devices needed for these data
as well as the advanced computer workstations needed to
perform accurate 3D quantification. Three-dimensional
measurement is not addressed within the new criteria but
may be important in the future, particularly with the advent
of highly sophisticated volumetric scanning techniques
(including multichannel CT and volumetric MRI) capable
of acquiring isotropic imaging data. The use of 3D volume
measurement has already been substantiated in several
studies (Eggli et al, 1995; Johnson et al, 1995; Sohaib et al,
2000; Sorenson et al, 2001).
* Lymph node involvement by tumour is different from other
common soft tissue tumour sites. It is well recognised,
especially in the radiology literature, that lymph nodes
should be measured in the short axis dimension as this is the
best predictor of the presence of metastatic disease (Kim et al,
1994) (Figure 1). Furthermore, in complete remission after
treatment, lymph nodes return to normal size yet the nodes
may remain visible. However, complete remission cannot be
designated to such nodes because the normal size of the
nodes on an individual basis is not known. Specialised
criteria have already been created to address this issue in
non-Hodgkin’s lymphomas (Cheson et al, 1999). Similar
difficulties apply to designating complete remission in other
structures, for example, the adrenal glands, the vaginal vault,
bladder wall, etc.
* Most tumours within the body (except lung metastases) grow
irregularly and also regress in an irregular manner. It is true,
and has been well documented that at baseline or any one
time point, there is good correlation between the maximal
tumour diameter, bidimensional measurement and tumour
volume. However, tumours do not necessarily grow or shrink
in a rounded fashion. In fact, lymph nodes frequently grow to
a greater extent in the short axis (Jeong et al, 2003).
Therefore, measurement of the longest diameter on sequen-
tial scans may not represent the true response.
* Issues surrounding cystic tumours are problematic. The
RECIST states that cystic lesions should be regarded as
nonmeasurable. Many lesions have cystic/necrotic centres
that may change on treatment and indeed metastases in the
liver may be cystic de novo (e.g. non-seminomatous germ cell
tumours, ovarian cancer). While it is recognised that certain
‘cystic tumours’ increase in size on effective treatment (e.g.
non-seminomatous germ cell tumour metastases; Husband
et al, 1982), the statement that all cystic lesions should be
regarded as nonmeasurable is, in our view, too wide.
Although tumours with cystic/necrotic centres should be
avoided as targets if possible, tumours with cystic/necrotic
centres may also be included in the assessment but a
comment should be made documenting changes in tumour
composition. In those tumour types where the phenomenon
of ‘cystic enlargement’ is well recognised, for example, non-
seminomatous germ cell tumours, appropriate note should be
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consistency such as calcification, necrosis or haemorrhage.
These phenomena, which may develop only on treatment,
may influence changes in tumour size. While such phenom-
ena have no clear prognostic implications (Hale et al, 1998),
it is only by documentation of such findings that progress in
assessing response with morphological assessment will be
made.
* Another potential pitfall in simple tumour measurements in
response assessment is the issue of lesion calcification.
Calcification in response assessment may be seen in
metastases to the lymph nodes, liver or peritoneum.
Response assessment is not well assessed by simple
measurement in these cases (Figure 2).
* Other types of lesions are also difficult to measure
unidimensionally or for that matter bidimensionally. For
instance, en-plaque lesions frequently diminish in the short
axis plane rather than in their long axis. Furthermore, the
measurement of en-plaque lesion length can be particularly
difficult as the plane of imaging is frequently in the same
plane as the long axis of tumour growth.
* For the first time, the RECIST criteria have provided imaging
guidelines for both spiral and conventional CT, which is
commendable and a great achievement, as it has standardised
imaging protocols across sites performing these studies. The
rapid advancement of imaging technology over the last few
years has, however, rendered the protocols detailed in
Appendix I outdated in many radiology departments under-
taking clinical trials. These protocols require updating for
multidetector CT. Such protocols should be reviewed on a
regular basis. It would be preferable for criteria such as
RECIST to provide a guideline for the selection of imaging
modalities and technologies and standard mechanisms for
creating disease- and modality-specific imaging protocols. In
this manner, the precise clinical trial protocols could be
defined based upon these guidelines and the more general
RECIST criteria would still be relevant. For example, as
outlined in RECIST, the specific concept of slice thickness
relative to spiral CT data acquisition is already obsolete, but a
general mechanism of defining slice thickness relative to
lesion size would still be relevant.
* In the RECIST criteria, the authors state that it is not
acceptable to switch between windows when measuring
lesions, but ‘in the lung it does not really matter whether
lung or soft tissue windows are used for intraparenchymal
lesions’. We do not agree with this statement, which may be
misleading to the uninitiated. It is possible to see substantial
differences in size and texture of lung lesions by viewing
them on lung and soft tissue windows. It is our recommenda-
tion that the window settings must be optimised to best
visualise the lesion, and lesions should be viewed on multiple
window settings but consistent windowing must be used for
subsequent assessments. We believe that the lung window
settings are the optimal ones for obtaining measurements of
all parenchymal lesions.
* There are new, novel methods of assessing disease response
in areas, such as bone, that are difficult to assess, and have
been considered nonmeasureable according to RECIST. For
instance, there is now evidence that MR imaging may be a
useful method of assessing response to therapy both in breast
cancer and in other tumours (Carlson et al, 1995; Brown et al,
Figure 2 Partially calcified liver metastases from colorectal cancer
imaged at baseline (A) and at a 6-week interval follow-up (B). The soft
tissue masses surrounding the calcification have decreased in size – the
overall mass including the calcification has either stayed stable or increased.
Figure 1 Patient with non-small cell lung cancer on chemotherapy.
Evidence of enlarged subcarinal lymph node measuring 3.42.9cm at
baseline (A), which has decreased in size to 3.42.0cm at subsequent
follow-up (B).
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l1998; Ciray et al, 2001). Other tumour types including
prostate are not amenable to assessment by RECIST since the
burden of disease in many patients is in the bone.
* Although the sum of all lesions measured provides an
indication of total tumour burden, such arithmetic sums may
disguise differential tumour response. Such discrepancy of
response has not been addressed with the new RECIST
criteria.
* A guideline concerning the number of lesions to include in
measurement is helpful and an advantage of RECIST over the
WHO criteria, which provided no directives in this regard. In
fact, cooperative groups have adopted a specific number of
lesions by appending the RECIST criteria. However, to our
knowledge, there is no evidence provided for the scientific
basis of the need to measure multiple lesions (up to 10
lesions). Interestingly, Cheson in a report of an international
workshop to standardise response criteria for non-Hodgkin’s
lymphomas noted a paucity of data for the number of lesions
to measure and included an arbitrary number in their
criteria, but left open to further discussion. The critical issue
is in fact the number of lesions that are needed to be
measured to have a consistent response assessment—either
by the same observer or another observer, that is, to decrease
variability in response assessment based upon choosing a
different set of lesions. Preliminary data and experience
would suggest that for certain tumours it is not necessary to
measure as many as 10 lesions (Schwartz et al, 2003b).
 We agree that intravenous administration of contrast medium is
an essential component of examination of the liver. However,
there are several potential pitfalls in measurements of liver
lesions. For example, there is no indication of whether liver
metastases should be measured including the ‘enhancing rim’ or
whether only the ‘central lower density component’ should be
measured on CT.
 It is difficult, but becoming increasingly important, to
standardise the approach to administering intravenous contrast
medium between different centres. We appreciate that this
would be difficult, but working towards a standardised
approach is of considerable importance. For example, measure-
ment of a liver lesion in the ‘arterial phase’ of enhancement will
produce a different measurement from that produced if the
lesion is measured in the ‘portal phase’ of enhancement
(Figure 3). Although the authors state that ‘a suitable contrast
agent should be given so that the metastases are demonstrated
to best effect and a consistent method is used on subsequent
examinations for any given patient’, there is no attempt to
standardise such an approach across a clinical trial. Therefore,
in one institution, a completely different method of assessing
liver metastases could be conducted compared with another
institution within the same study, leading to major discrepan-
cies and probable error! (Nazarian et al, 1999).
 It is important to raise our concern regarding the frequency and
intensity of imaging required to assess therapeutic response as it
relates to radiation exposure. In many clinical protocols,
sequential examinations of the chest, abdomen and pelvis are
required following every two cycles of chemotherapy. The
adoption of multidetector CT scanning and thin collimation
slices raises the important issue of radiation dosage to the
patient, a topic that is becoming increasingly important, and
addressed by other consensus statements in the imaging
community (Brix et al, 2003; Mayo et al, 2003).
 There is room for debate and discussion regarding the need for
CT scans of the chest, abdomen, pelvis and sometimes the neck
during follow-up in patients with certain tumours in whom
multiple CT scans are performed over a considerable length of
time (e.g. lymphoma or testicular tumours). Reduction in the
radiation dose could be achieved by limiting follow-up CT scans
to the area(s) of disease, or the most likely sites of relapse
(Thomas et al, 1982; Wright and White, 1999; Boger-Megiddo
et al, 2002). Radiation dose is also of great concern in the
follow-up of paediatric tumours.
 Unfortunately, many clinical trials are discussed and agreed
with clinical principal investigators and diagnostic radiologists
are only involved after the protocol has been agreed. It is the
view of the ICIS that a radiologist should be a prominent
member of the clinical research team when new clinical trials
are being developed. It should be the responsibility of both the
principal investigator and of industry to recognise the pivotal
role of diagnostic imaging, not only in evaluation of response
but also in setting up clinical trials from the outset.
 The ICIS would suggest that in selected trials, off-site
independent review of imaging data is undertaken by expert
oncological radiologists who have experience in this subspeci-
alty of diagnostic radiology. This is frequently not the case. The
RECIST criteria have been set up in order to improve the
accuracy and reproducibility of reporting of clinical trials
among multiple sites and trials, but if the adoption of such
criteria is unworkable for technical and practical purposes, the
major objective is unlikely to be realised. Currently, commercial
organisations, contract research organisations, cooperative
groups and governmental agencies conduct independent
response assessment. Many aspects of these external reviews,
including, but not limited to, the use of film versus digital image
data, number of external reviewers, format of the external
review, use of clinical data in addition to image data, are not
standardised. This lack of uniformity may lead to differences in
response assessment, independent of the measurement metho-
dology utilised. These differences have not been well studied or
even documented in the oncology or radiology literature.
Observer variability is also a major issue in response assess-
Figure 3 Visualisation of liver metastases is greatly influenced by phase
of contrast administration. Note nonvisualisation of lesions in the
equilibrium phase (A), which are seen in the arterial phase (B) (arrows).
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lment. Data suggest that measurements made by a limited
number of experienced observers should increase the accuracy
in quantitative analysis of medical images (Belton et al, 2003).
 It is interesting to note that several radiologists working in
cancer imaging have stated that recent trials have been set up
with protocols that state that either RECIST or WHO or
modifications of both criteria may be used. Further, disease-
specific guidelines have been proposed, which are being used in
many cooperative group trials (Cheson et al, 1999). It seems that
a standardised approach is far from being realised.
We propose that a working party of the ICIS enters a dialogue
with the authors of the New Guidelines to Evaluate Response of
Solid Tumours (RECIST) in order to modify and update the
guidelines in accordance with current opinion as outlined above.
We propose that such dialogue should be ongoing so that new
information from existing and new technology can be introduced
into the guidelines in the future in a timely and appropriate
manner. For example, there is clearly a growing need to introduce
a multimodality approach to monitoring tumour response, thereby
integrating morphological and functional tumour measurements.
The rapidly growing application of positron emission tomography
(PET), PET/CT and MRI to monitoring tumour response provides
this opportunity and opens the way to a new and exciting era in
cancer imaging.
ACKNOWLEDGEMENTS
We acknowledge the advice of Dr Anwar Padhani in the prepara-
tion of this document.
REFERENCES
Belton AL, Saini S, Liebermann K, Boland GW, Halpern EF (2003) Tumor
size measurement in an oncology clinical trial: comparison between off-
site and on-site measurements. Clin Radiol 58: 311–314
Boger-Megiddo I, Apter S, Spencer JA, Ben-Yehuda D, Nof E, Libson E
(2002) Is chest CT sufficient for follow-up of primary mediastinal B-cell
lymphoma in remission? Am J Roentgenol 178: 165–167
Brix G, Nagel HD, Stamm G, Veit R, Lechel U, Griebel J, Galanski M (2003)
Radiation exposure in multi-slice versus single-slice spiral CT: results of
a nationwide survey. Eur Radiol 13: 1979–1991
Brown AL, Middleton G, MacVicar AD, Husband JES (1998) T1-weighted
magnetic resonance imaging in breast cancer vertebral metastases:
changes on treatment and correlation with response to therapy. Clin
Radiol 53: 493–501
Carlson K, A ˚stro ¨m G, Nyman R, Ahlstrom H, Simonsson B (1995) MR
imaging of multiple myeloma in tumour mass measurement at diagnosis
and during treatment. Acta Radiol 36: 9–14
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM,
Lister TA, Vose J, Grillo-Lo ´pez A, Hagenbeek A, Cabanillas F,
Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO,
Carter W, Hoppe R, Canellos GP (1999) Report of an international
workshop to standardize response criteria for non-Hodgkin’s lympho-
mas. NCI Sponsored International Working Group. J Clin Oncol 17: 1244
Ciray I, Lindman H, A ˚stro ¨m G, Bergh J, Ahlstrom KH (2001) Early response
of breast cancer bone metastases to chemotherapy evaluated with MR
imaging. Acta Radiol 42: 198–206
Eggli KD, Close P, Dillon PW, Umlauf M, Hopper KD (1995) Three-
dimensional quantitation of pediatric tumor bulk. Pediatr Radiol 25: 1–6
Hale HL, Husband JE, Gossios K, Norman AR, Cunningham D (1998) CT of
calcified liver metastases in colorectal carcinoma. Clin Radiol 53: 735–
741
Husband JE, Hawkes DJ, Peckham MJ (1982) CT estimations of mean
attenuation values and volume in testicular tumours: a comparison with
surgical and histologic findings. Radiology 144: 553–558
Jeong YY, Kang HK, Chung TW, Seo JJ, Park JG (2003) Uterine cervical
carcinoma after therapy: CT and MR imaging findings. Radiographics 23:
969–981
Johnson CR, Khandelwal SR, Schmidt-Ullrich RK, Ravalese III J, Wazer DE
(1995) The influence of quantitative tumor volume measurements on
local control in advanced head and neck cancer using concomitant boost
accelerated superfractionated irradiation. Int J Radiat Oncol Biol Phys 32:
635–641
Kim SH, Kim SC, Choi BI, Han MC (1994) Uterine cervical carcinoma:
evaluation of pelvic lymph node metastasis with MR imaging. Radiology
190: 807–811
Mayo JR, Aldrich J, Mu ¨ller NL (2003) Radiation exposure at chest CT: a
statement of the Fleischner Society. Radiology 228: 15–21
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of
cancer treatment. Cancer 47: 207–214
Nazarian LN, Park JH, Halpern EJ, Parker L, Johnson PT, Lev-Toaff AS,
Wechsler RJ (1999) Size of colorectal liver metastases at abdominal CT:
comparison of precontrast and postcontrast studies. Radiology 213: 825–
830
Prasad SR, Jhaveri KS, Saini S, Hahn PF, Halpern EF, Sumner JE (2002) CT
tumor measurement for therapeutic response assessment: comparison of
unidimensional, bidimensional, and volumetric techniques initial
observations. Radiology 225: 416–419
Schwartz LH, Heinze S, Sgouros G, Kolbert K, Panicek DM (2001) Do one,
two, or three dimensions need to be measured to assess tumor
progression or response?. Proceedings of the Radiological Society of
North America , p 438, abstract no. 868
Schwartz LH, Mazumdar M, Wang L, Smith A, Marion S, Panicek DM,
Motzer RJ (2003a) Response assessment classification in patients with
advanced renal cell carcinoma treated on clinical trials. Cancer 98: 1611–
1619
Schwartz LH, Mazumdar M, Brown W, Smith A, Panicek DM (2003b)
Variability in response assessment in solid tumors: effect of number of
lesions chosen for measurement. Clin Cancer Res 9: 4318–4323
Sohaib SA, Turner B, Hanson JA, Farquharson M, Oliver RT, Reznek RH
(2000) CT assessment of tumour response to treatment: comparison of
linear, cross-sectional and volumetric measures of tumour size. Br J
Radiol 73: 1178–1184
Sorensen AG, Patel S, Harmath C, Bridges S, Synnott J, Sievers A, Yoon YH,
Lee EJ, Yang MC, Lewis RF, Harris GJ, Lev M, Schaefer PW, Buchbinder
BR, Barest G, Yamada K, Ponzo J, Kwon HY, Gemmete J, Farkas J,
Tievsky AL, Ziegler RB, Salhus MR, Weisskoff R (2001) Comparison of
diameter and perimeter methods for tumor volume calculation. J Clin
Oncol 19: 551–557
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein
L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther
SG (2000) New guidelines to evaluate the response to treatment in solid
tumours. European Organization for Research and Treatment of Cancer,
National Cancer Institute of United States, National Cancer Institute of
Canada. J Natl Cancer Inst 92: 205–216
Thiesse P, Ollivier L, Di Stefano-Louineau D, Negrier S, Savary J, Pignard K,
Lasset C, Escudier B (1997) Response rate accuracy in oncology trials:
reasons for interobserver variability. Groupe Francais d’Immunotherapie
of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin
Oncol 15: 3507–3514
Thomas JL, Barnes PA, Bernardino ME, Hagemeister FB (1982) Limited CT
studies in monitoring treatment of lymphoma. Am J Roentgenol 138:
537–539
Wang L, Schwartz LH, Mazumdar M, Smith A, Kemeny N, Panicek DM
(2003) Impact of measurement technique on response assessment
criteria in colorectal cancer. Proceedings of the American Society of
Clinical Oncology , p 278, abstract no. 1114
Warren KE, Patronas N, Aikin AA, Albert PS, Balis FM (2001) Comparison
of one-, two-, and three-dimensional measurements of childhood brain
tumors. J Natl Cancer Inst 93: 1401–1405
Wright AR, White PM (1999) Testicular cancer – who needs surveillance
pelvic CT? Clin Radiol 54: 78
Evaluation of the response to treatment of solid tumours
JE Husband et al
2260
British Journal of Cancer (2004) 90(12), 2256–2260 & 2004 Cancer Research UK
C
l
i
n
i
c
a
l